PortfoliosLab logoPortfoliosLab logo
PRME vs. NTLA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PRME vs. NTLA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and Intellia Therapeutics, Inc. (NTLA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PRME achieves a -15.85% return, which is significantly lower than NTLA's 18.80% return.


PRME

1D
-3.31%
1M
-24.55%
6M
-23.36%
YTD
-15.85%
1Y
-27.72%
3Y*
-41.84%
5Y*
10Y*
ALL TIME*
-39.06%

NTLA

1D
-3.70%
1M
-39.18%
6M
-18.78%
YTD
18.80%
1Y
-7.05%
3Y*
-36.11%
5Y*
-40.39%
10Y*
-5.06%
ALL TIME*
-6.82%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$37.16M$55.27M$78.35M
$7.89M$13.77M$11.21M

PRME vs. NTLA - Yearly Performance Comparison


2026 (YTD)2025202420232022
PRME
Prime Medicine Inc. Common Stock
-15.85%18.84%-67.04%-52.31%-2.06%
NTLA
Intellia Therapeutics, Inc.
18.80%-22.90%-61.76%-12.61%-33.80%

Correlation

The correlation between PRME and NTLA is 0.67, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.67

Correlation (3Y)
Balances recent behavior with more history.

0.63

Correlation (All Time)
Calculated using the full available price history since Oct 20, 2022

0.59

The correlation between PRME and NTLA has been stable across timeframes, ranging from 0.59 to 0.67 - a consistent structural relationship.

Fundamentals

Market Cap

PRME:

$527.40M

NTLA:

$1.20B

EPS

PRME:

-$1.22

NTLA:

-$3.51

PS Ratio

PRME:

148.96

NTLA:

18.16

PB Ratio

PRME:

6.74

NTLA:

2.04

Total Revenue (TTM)

PRME:

$3.18M

NTLA:

$66.09M

Gross Profit (TTM)

PRME:

-$4.14M

NTLA:

-$33.92M

EBITDA (TTM)

PRME:

-$195.72M

NTLA:

-$299.32M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PRME vs. NTLA — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

PRME
PRME Risk / Return Rank: 3636
Overall Rank
PRME Sharpe Ratio Rank: 3434
Sharpe Ratio Rank
PRME Sortino Ratio Rank: 4040
Sortino Ratio Rank
PRME Omega Ratio Rank: 3939
Omega Ratio Rank
PRME Calmar Ratio Rank: 3232
Calmar Ratio Rank
PRME Martin Ratio Rank: 3434
Martin Ratio Rank

NTLA
NTLA Risk / Return Rank: 4545
Overall Rank
NTLA Sharpe Ratio Rank: 4141
Sharpe Ratio Rank
NTLA Sortino Ratio Rank: 5050
Sortino Ratio Rank
NTLA Omega Ratio Rank: 5050
Omega Ratio Rank
NTLA Calmar Ratio Rank: 4141
Calmar Ratio Rank
NTLA Martin Ratio Rank: 4141
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

PRME vs. NTLA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PRMENTLADifference
Sharpe ratioReturn per unit of total volatility

-0.16

Sortino ratioReturn per unit of downside risk

-0.35

Omega ratioGain probability vs. loss probability

1.03

1.08

-0.06

Calmar ratioReturn relative to maximum drawdown

-0.37

-0.12

-0.25

Martin ratioReturn relative to average drawdown

-0.54

-0.17

-0.37

PRME vs. NTLA - Sharpe Ratio Comparison

The current PRME Sharpe Ratio is -0.24, which is lower than the NTLA Sharpe Ratio of -0.08. The chart below compares the historical Sharpe Ratios of PRME and NTLA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PRME vs. NTLA - Drawdown Comparison

The maximum PRME drawdown since its inception was -94.55%, roughly equal to the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for PRME and NTLA.


Loading charts...

Drawdown Indicators


PRMENTLADifference

Max Drawdown

Largest peak-to-trough decline

-94.55%

-96.45%

+1.90%

Max Drawdown (1Y)

Largest decline over 1 year

-59.52%

-71.27%

+11.75%

Max Drawdown (3Y)

Largest decline over 3 years

-91.64%

-84.31%

-7.33%

Max Drawdown (5Y)

Largest decline over 5 years

-96.45%

Max Drawdown (10Y)

Largest decline over 10 years

-96.45%

Current Drawdown

Current decline from peak

-86.17%

-93.96%

+7.79%

Average Drawdown

Average peak-to-trough decline

-66.15%

-57.56%

-8.59%

Ulcer Index

Depth and duration of drawdowns from previous peaks

40.94%

48.81%

-7.87%

Volatility

PRME vs. NTLA - Volatility Comparison

Prime Medicine Inc. Common Stock (PRME) has a higher volatility of 24.52% compared to Intellia Therapeutics, Inc. (NTLA) at 18.85%. This indicates that PRME's price experiences larger fluctuations and is considered to be riskier than NTLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PRMENTLADifference

Volatility (1M)

Calculated over the trailing 1-month period

24.52%

18.85%

+5.67%

Volatility (6M)

Calculated over the trailing 6-month period

55.01%

56.80%

-1.79%

Volatility (1Y)

Calculated over the trailing 1-year period

90.13%

98.08%

-7.95%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

90.24%

78.01%

+12.23%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

90.24%

78.82%

+11.42%

Dividends

PRME vs. NTLA - Dividend Comparison

Neither PRME nor NTLA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PRME vs. NTLA - Financials Comparison

This section allows you to compare key financial metrics between Prime Medicine Inc. Common Stock and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


PRME and NTLA have a correlation of 0.67, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PRME has higher volatility (24.52%) compared to NTLA (18.85%). In terms of maximum drawdown, PRME dropped -94.55% vs NTLA's -96.45%.

NTLA currently has the higher Sharpe Ratio (-0.08 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PRME and NTLA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer